Presence of AR-V7 splice variant or AR C terminal loss in the CTCs of mCRPC patients identifies patients with improved PSA response with taxanes over androgen receptor signaling directed therapies (ARS Rx) Meeting Abstract

  

Authors:	Scher, H. I.; Kelvin, J.; Lu, D.; Louw, J.; Packer, D.; Bambury, R.; Rathkopf, D.; Schreiber, N.; Brennan, R.; Prigozhina, N.; Brown, D.; Jendrisak, A.; Dugan, L.; Landers, M.; Lee, F.; Fleisher, M.; Marrinucci, D.; Dittamore, R.
Abstract Title:	Presence of AR-V7 splice variant or AR C terminal loss in the CTCs of mCRPC patients identifies patients with improved PSA response with taxanes over androgen receptor signaling directed therapies (ARS Rx)
Meeting Title:	18th European Cancer Conference (ECCO 18)
Journal Title:	European Journal of Cancer
Volume:	51
Issue:	Suppl. 3
Meeting Dates:	2015 Sep 25-29
Meeting Location:	Vienna, Austria
ISSN:	0959-8049
Publisher:	Elsevier Inc.
Date Published:	2015-09-01
Start Page:	S93
Language:	English
ACCESSION:	WOS:000361887400285
PROVIDER:	wos
DOI:	10.1016/S0959-8049(16)30278-7
Notes:	Meeting Abstract: 444 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/82681